Skip to main content
v2026.11,986 entries · CC-BY 4.0

Editorial · CASRAI · Clinical research and clinical trials

WHO to add two Bundibugyo vaccine candidates to Tumaini Ebola trial as DR Congo cases pass 11,000

WHO says two Bundibugyo-specific vaccine candidates will join the Tumaini trial as DR Congo’s Ebola outbreak more than doubles in three months.

Published 18 Nov 2026· 5 minute read

Ask CASRAI · free to try

Ask about this story

2 free questions a day, no account.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

CASRAI is the reference for research administration — bookmark it for the next question.

On 17 November 2026 the World Health Organization said two vaccine candidates developed specifically for Bundibugyo virus will be added to its Tumaini vaccine trial in the Democratic Republic of the Congo, as the outbreak has more than doubled in three months. The step follows the trial’s launch on 23 October and extends the August prioritisation of Bundibugyo vaccines for trial-only deployment.

What happened

WHO Director-General Tedros Adhanom Ghebreyesus gave the update on 17 November at the third meeting of the International Health Regulations Emergency Committee on Bundibugyo virus disease, according to UN News. He said cases had more than doubled in three months, with more than 11,000 cases and 5,400 deaths reported across 67 health zones in eight provinces, and 400 to 500 new cases still reported each week.

On the vaccines, UN News reports that two candidates developed specifically for Bundibugyo virus will be added to an ongoing vaccine trial in the coming weeks. In a Geneva press conference quoted by AFP, Tedros said: “We expect two candidate vaccines developed specifically for Bundibugyo virus to begin testing as early as next week.”

Key details

The two candidates, as AFP and WHO describe them, are:

  • ChAdOx1, an adenoviral vector vaccine developed by the University of Oxford. WHO’s Disease Outbreak News names the Serum Institute of India as a partner on this candidate.
  • mRNA-1469, an mRNA vaccine developed by Moderna.

AFP reports that both have completed earlier, smaller Phase 1 trials. WHO’s Disease Outbreak News of 6 November says WHO expert groups recommended adding both candidates and that each will enter the trial only after national approvals. No vaccine or specific treatment is approved for Bundibugyo virus, WHO states.

Tumaini is a platform trial: a single framework that tests the safety, efficacy and immune response of several vaccines. WHO describes it as a Phase 2/3 study that enrolled its first participants in Bunia, in Ituri Province, on 23 October. AFP adds that:

  • Ervebo, which is approved for the Zaire species of Ebola virus, began Phase 3 testing in Tumaini on 23 October to see whether it also protects against Bundibugyo;
  • the trial uses ring vaccination, immunising high-risk contacts of infected people;
  • more than 140 people have enrolled so far, with thousands of contacts expected to join;
  • it currently runs at one site in Bunia and is to expand beyond it;
  • Meg Doherty, head of WHO’s science for health department, said Phase 2 trials of the two candidates are scheduled to begin on 26 or 27 November in Bunia, and that they would advance to Phase 3 only if Phase 2 safety and immune-response data pass review.

Case counts differ by source and cut-off date, as the table shows.

Source Confirmed cases Deaths Date or cut-off
WHO Disease Outbreak News (DRC) 10,668 5,198 As of 3 November 2026
Al Jazeera, citing government data 11,042 at least 5,387 Released 10 November 2026
AFP, citing WHO 11,376 5,568 Reported 17 November 2026
UN News, WHO Director-General more than 11,000 5,400 Stated 17 November 2026

Background and context

AFP reports that the outbreak was declared in May, triggered an international public health emergency and is the DRC’s worst Ebola outbreak. Al Jazeera, with Reuters, calls it the second-largest and second-deadliest on record, behind the 2014-2016 West African outbreak, which infected more than 28,600 people. It says Bundibugyo kills about half of those it infects, and that delayed detection, conflict and strained health services have let it spread faster than earlier outbreaks. See public health emergency declarations for how these designations work.

WHO’s 6 November report put crude case fatality at 48.7 per cent, with 7,485 cases in Ituri and 2,593 in Nord-Kivu. It records nine confirmed cases and two deaths in Kenya and one imported case in Nigeria, and says contact follow-up averaged 86 per cent against a 95 per cent target. Al Jazeera reports that WHO approved clinical trials of two new vaccines earlier in November and expects results in early 2027.

Reaction

Tedros said children were “paying a terrible price”: they account for more than a quarter of confirmed cases and a third of deaths, and seven in ten children under five with confirmed Ebola have died. He said two-thirds of confirmed deaths occurred outside Ebola treatment centres, which suggests infections are being identified too late, and that the number of laboratories able to test for the virus rose from two to more than two dozen. He warned: “The risk beyond the DRC’s borders is not theoretical,” and “progress in some places is not control of the outbreak as a whole.” He also criticised blanket travel restrictions as hindering the response, a position WHO’s outbreak report repeats.

What it means for researchers, universities and research offices

For vaccine developers, the announcement shows how a platform trial lets candidates enter an existing protocol and site network instead of each starting a separate study. Entry is gated by national approvals and by Phase 2 safety and immune-response review, so timelines depend on regulators and review bodies in the DRC as much as on manufacturing. Teams planning comparable work can read how master protocol designs differ and how data safety monitoring boards and trial phases govern progression between stages.

For funders and research offices, the reported single-site operation and planned expansion mean that site capacity, laboratory testing and community engagement are the working constraints. The rise in testing laboratories from two to more than two dozen is the kind of capacity that sponsored research partners will need to coordinate with. Offices handling outbreak-related sponsored work should expect that the candidates come from an academic developer (Oxford) and an industry developer (Moderna), so agreements will span university, company and WHO-coordinated trial structures. The approach of the Oxford candidate is explained in the guide to viral vector vaccines.

What happens next

Tedros said testing of the two candidates could begin as early as the week after 17 November. Doherty said Phase 2 trials of both candidates are scheduled for 26 or 27 November in Bunia, with Phase 3 only if Phase 2 data pass review. Al Jazeera reports that WHO expects vaccine results in early 2027. The trial is also to expand beyond Bunia, and each new candidate requires national approval before entry.

Sources

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →